(Q48618698)

13 February 2018

title

Incidence and characteristics of melanoma brain metastases developing during treatment with vemurafenib (English)

1 reference

13 February 2018

1 reference

L Peuvrel

1

1 reference

13 February 2018

M Saint-Jean

2

1 reference

13 February 2018

G Quéreux

3

1 reference

13 February 2018

A Brocard

4

1 reference

13 February 2018

A Khammari

5

1 reference

13 February 2018

A C Knol

6

1 reference

13 February 2018

B Dréno

7

1 reference

13 February 2018

publication date

7 August 2014

1 reference

13 February 2018

Journal of Neuro-Oncology

published in

1 reference

13 February 2018

volume

120

1 reference

13 February 2018

issue

1

1 reference

13 February 2018

page(s)

147-154

1 reference

13 February 2018

Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1533-Z

Melanoma brain metastasis: overview of current management and emerging targeted therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1533-Z

Brain metastases: pathobiology and emerging targeted therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1533-Z

The use of systemic therapies for the treatment of brain metastases in metastatic melanoma: opportunities and unanswered questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1533-Z

Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1533-Z

Treatment of metastatic malignant melanoma with vemurafenib during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1533-Z

Melanoma brain metastases and vemurafenib: need for further investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1533-Z

Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1533-Z

Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1533-Z

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1533-Z

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1533-Z

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1533-Z

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1533-Z

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1533-Z

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1533-Z

Melanoma--an unlikely poster child for personalized cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1533-Z

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1533-Z

Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1533-Z

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1533-Z

The blood-brain barrier: its influence in the treatment of brain tumors metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1533-Z

Vemurafenib and radiation therapy in melanoma brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1533-Z

Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1533-Z

Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1533-Z

Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases: a retrospective review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1533-Z

Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1533-Z

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1533-Z

Prognostic factors for survival in melanoma patients with brain metastases

21 January 2018

1 reference

12 December 2020

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases

1 reference

12 December 2020

Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer?

1 reference

12 December 2020

Severe radiotherapy-induced extracutaneous toxicity under vemurafenib

1 reference

12 December 2020

Dabrafenib and its potential for the treatment of metastatic melanoma

1 reference

12 December 2020

10.1007/S11060-014-1533-Z

Identifiers

DOI

1 reference

13 February 2018

1 reference

13 February 2018